PL424035A1 - Optymalnie aktywowane komórki dendrytyczne, które indukują ulepszoną lub zwiększoną przeciwnowotworową odpowiedź odpornościową - Google Patents

Optymalnie aktywowane komórki dendrytyczne, które indukują ulepszoną lub zwiększoną przeciwnowotworową odpowiedź odpornościową

Info

Publication number
PL424035A1
PL424035A1 PL424035A PL42403516A PL424035A1 PL 424035 A1 PL424035 A1 PL 424035A1 PL 424035 A PL424035 A PL 424035A PL 42403516 A PL42403516 A PL 42403516A PL 424035 A1 PL424035 A1 PL 424035A1
Authority
PL
Poland
Prior art keywords
dendritic cells
optimally
cancer
partially
antitumor immunity
Prior art date
Application number
PL424035A
Other languages
English (en)
Inventor
Marnix L. Bosch
Original Assignee
Northwest Biotherapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest Biotherapeutics, Inc. filed Critical Northwest Biotherapeutics, Inc.
Publication of PL424035A1 publication Critical patent/PL424035A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C12N5/064—Immunosuppressive dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/72—Undefined extracts from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Przedmiotem zgłoszenia jest sposób wytwarzania wyizolowanych częściowo dojrzałych i optymalnie aktywnych ludzkich komórek dendrycznych. Zgłoszenie obejmuje także kompozycję zawierającą częściowo dojrzałe i optymalnie aktywowane ludzkie komórki dendryczne, które można zastosować do podawania osobom mającym raka i/lub nowotwór. Częściowo dojrzałe komórki dendrytyczne, te, które kontaktowano z czynnikiem dojrzewania komórek dendrytycznych przez około 10 do około 19 godzin, podczas podawania skutecznie pobierają i przetwarzają antygeny nowotworowe w obszarze miejsca nowotworu, kończą dojrzewanie, a następnie mogą migrować do węzłów chłonnych leczonej osoby. Gdy znajdą się w węźle chłonnym, w pełni dojrzałe komórki dendrytyczne prezentujące antygen wydzielają odpowiednie cytokiny (np. TNF?, IL-6, IL-8, i/lub IL-12) i kontaktują się z komórkami T indukując znaczną i optymalną kliniczną i/lub przeciwnowotworową odpowiedź odpornościową.
PL424035A 2015-06-30 2016-06-29 Optymalnie aktywowane komórki dendrytyczne, które indukują ulepszoną lub zwiększoną przeciwnowotworową odpowiedź odpornościową PL424035A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562187086P 2015-06-30 2015-06-30
PCT/US2016/040134 WO2017004230A1 (en) 2015-06-30 2016-06-29 Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response

Publications (1)

Publication Number Publication Date
PL424035A1 true PL424035A1 (pl) 2019-01-02

Family

ID=57609106

Family Applications (1)

Application Number Title Priority Date Filing Date
PL424035A PL424035A1 (pl) 2015-06-30 2016-06-29 Optymalnie aktywowane komórki dendrytyczne, które indukują ulepszoną lub zwiększoną przeciwnowotworową odpowiedź odpornościową

Country Status (15)

Country Link
US (2) US11124768B2 (pl)
EP (1) EP3317403A4 (pl)
JP (2) JP6985939B2 (pl)
KR (1) KR20180022949A (pl)
CN (2) CN107849537A (pl)
AR (1) AR106496A1 (pl)
AU (2) AU2016286112B2 (pl)
BR (1) BR112017028602A2 (pl)
CA (1) CA2990640A1 (pl)
HK (1) HK1255084A1 (pl)
IL (1) IL256522B1 (pl)
MX (2) MX2018000056A (pl)
PL (1) PL424035A1 (pl)
RU (1) RU2018103235A (pl)
WO (1) WO2017004230A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018160666A1 (en) * 2017-02-28 2018-09-07 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Short-term activated dc1s and methods for their production and use
CN117417886B (zh) * 2023-10-20 2024-05-14 广东壹加再生医学研究院有限公司 一种负载肿瘤抗原的树突状细胞激活的t淋巴细胞的培养方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040203143A1 (en) * 2003-02-27 2004-10-14 Northwest Biotherapeutics, Inc. Generation of dendritic cells from monocytic dendritic precursor cells with GM-CSF in the absence of additional cytokines
JP2015107133A (ja) * 2001-09-06 2015-06-11 ノースウエスト バイオセラピューティクス，インコーポレイティド 単球性樹状細胞およびｔ細胞にｔｈ−１応答をプライミングするための組成物および方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
PT1567155E (pt) * 2002-12-06 2011-01-28 Northwest Biotherapeutics Inc Administração de células dendríticas parcialmente amadurecidas in vitro para o tratamento de tumores
KR100887560B1 (ko) 2007-04-24 2009-03-09 크레아젠 주식회사 준성숙 수지상 세포를 포함하는 류마티스 관절염 치료용약제학적 조성물
AU2008323853B8 (en) * 2007-11-08 2014-07-24 Beth Israel Deaconess Medical Center Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-CD3/CD28
EP2072617A1 (en) 2007-12-12 2009-06-24 Trimed Biotech GmbH Method for producing dendritic cells
DK2982753T3 (en) 2008-04-18 2018-09-03 Baxter Int Microsphere-based composition to prevent and / or reverse newly started autoimmune diabetes
WO2014149871A1 (en) * 2013-03-14 2014-09-25 Icahn School Of Medicine At Mount Sinai Autologous tumor lysate-loaded dendritic cell vaccine for treatment of liver cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015107133A (ja) * 2001-09-06 2015-06-11 ノースウエスト バイオセラピューティクス，インコーポレイティド 単球性樹状細胞およびｔ細胞にｔｈ−１応答をプライミングするための組成物および方法
US20040203143A1 (en) * 2003-02-27 2004-10-14 Northwest Biotherapeutics, Inc. Generation of dendritic cells from monocytic dendritic precursor cells with GM-CSF in the absence of additional cytokines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
F. SALLUSTO ET AL, "EFFICIENT PRESENTATION OF SOLUBLE ANTIGEN BY CULTURED HUMAN DENDRITIC CELLS IS MAINTAINED BY GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR PLUS INTERLEUKIN 4 AND DOWNREGULATED BY TUMOR NECROSIS FACTOR ALFA" J. EXP. MED. 1994, 179, 1994 *
M.B. LUTZ ET AL, "IMMATURE DENDRITIC CELLS GENERATED WITH LOW DOSES OF GM-CSF IN THE ABSENCE OF IL-4 ARE MATURATION RESISTANT AND PROLONG ALLOGRAFT SURVIVAL IN VIVO" EUR. J. IMMUNOL., 2000, 30, 2000 *

Also Published As

Publication number Publication date
MX2018000056A (es) 2018-05-28
CN114774356A (zh) 2022-07-22
US11124768B2 (en) 2021-09-21
JP2018523996A (ja) 2018-08-30
EP3317403A4 (en) 2019-07-03
KR20180022949A (ko) 2018-03-06
CN107849537A (zh) 2018-03-27
WO2017004230A1 (en) 2017-01-05
US20220145246A1 (en) 2022-05-12
IL256522B1 (en) 2024-06-01
AU2016286112A1 (en) 2018-02-15
MX2023001622A (es) 2023-03-09
RU2018103235A (ru) 2019-07-31
IL256522A (en) 2018-02-28
AU2023202977A1 (en) 2023-06-01
JP6985939B2 (ja) 2021-12-22
AR106496A1 (es) 2018-01-24
HK1255084A1 (zh) 2019-08-02
CA2990640A1 (en) 2017-01-05
JP2022023248A (ja) 2022-02-07
BR112017028602A2 (pt) 2018-09-04
AU2016286112B2 (en) 2023-02-16
RU2018103235A3 (pl) 2019-12-23
US20180187145A1 (en) 2018-07-05
EP3317403A1 (en) 2018-05-09

Similar Documents

Publication Publication Date Title
HK1082180A1 (en) Administration of dendritic cells partially matured in vitro for the treatment of tumors
Anderson et al. Adipose-derived mesenchymal stromal cells induce immunomodulatory macrophages which protect from experimental colitis and sepsis
Hotz et al. Reprogramming of TLR7 signaling enhances antitumor NK and cytotoxic T cell responses
MX2021001762A (es) Metodo y composicion para estimular la respuesta inmunitaria.
Núñez et al. IFNβ produced by TLR4-activated tumor cells is involved in improving the antitumoral immune response
AR004445A1 (es) Una composicion inmunogenica, una dosis unitaria, un metodo para producir la composicion, un kit para producir la composicion, una poblacion de celulas,uso de dicha poblacion celular y una preparacion combinada
RU2018145512A (ru) Биологические маркеры, которые могут быть использованы в иммунотерапии рака
PH12015502630A1 (en) Substituted tetrahydrocarbazole and carbazole carboxamide compounds useful as kinase inhibitors
PL424035A1 (pl) Optymalnie aktywowane komórki dendrytyczne, które indukują ulepszoną lub zwiększoną przeciwnowotworową odpowiedź odpornościową
Hwang et al. Bacteroides fragilis toxin induces IL-8 secretion in HT29/C1 cells through disruption of E-cadherin junctions
AR068984A1 (es) Proceso para la obtencion de celulas presentadoras de antigenos activados, utiles en las terapias contra el cancer y enfermedades relacionadas del sistema inmunologico
Hetta et al. Regulatory B cells: key players in hepatocellular carcinoma progression
Adotévi et al. Targeting antitumor CD4 helper T cells with universal tumor-reactive helper peptides derived from telomerase for cancer vaccine
Hibberd et al. Immunization strategies for the immunocompromised host: the need for immunoadjuvants
CA2754109A1 (en) Infectious disease cellular immunotherapy
Lee et al. TLR4-dependent effects of ISAg treatment on conventional T cell polarization in vivo
Ebadi et al. Plant components for immune modulation targeting dendritic cells: implication for therapy
Sun et al. Enhancement of immune response for Newcastle disease vaccine using a combined adjuvant solution of Astragalus polysaccharides, levamisole, and selenoprotein
JP2018523996A5 (pl)
MX2022004326A (es) Método para la inducción de antígenos asociados al tumor con briostatina.
EA202192459A1 (ru) Способ лечения псориаза антителом к il12/il23 у субъектов детского возраста
Bergler-Czop et al. Seborrhoeic dermatitis and a herpes zoster infection developed during treatment with adalimumab due to Crohn’s disease
Li et al. Pyoderma gangrenosum as the initial manifestation of small cell lung cancer with dermatomyositis
Blotskiy et al. THE USE OF LASER AND LED PHOTOTHERAPY IN THE TREATMENT OF CHRONIC TONSILLITIS
Iwashita et al. Potent stimuli combined with lipopolysaccaride and IFNγ may improve immunotherapy against HCC by increasing the maturation and subsequent immune response of the dendritic cells